20722491|t|Safety of capecitabine: a review.
20722491|a|IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years. AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety. WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease. We also explore different dosing and schedules of capecitabine administration. TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome. Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
20722491	10	22	capecitabine	ChemicalEntity	D000069287
20722491	59	76	Fluoropyrimidines	ChemicalEntity	-
20722491	92	106	5-fluorouracil	ChemicalEntity	D005472
20722491	108	112	5-FU	ChemicalEntity	D005472
20722491	169	175	tumors	DiseaseOrPhenotypicFeature	D009369
20722491	187	231	colorectal, breast and head and neck cancers	DiseaseOrPhenotypicFeature	D001943,D006258,D015179
20722491	333	345	capecitabine	ChemicalEntity	D000069287
20722491	467	479	capecitabine	ChemicalEntity	D000069287
20722491	511	519	patients	OrganismTaxon	9606
20722491	539	563	renal and kidney disease	DiseaseOrPhenotypicFeature	D007674
20722491	615	627	capecitabine	ChemicalEntity	D000069287
20722491	663	675	Capecitabine	ChemicalEntity	D000069287
20722491	698	702	5-FU	ChemicalEntity	D005472
20722491	913	998	colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers	DiseaseOrPhenotypicFeature	D001943,D002292,D006258,D010190,D013274,D015179
20722491	1044	1056	capecitabine	ChemicalEntity	D000069287
20722491	1061	1069	diarrhea	DiseaseOrPhenotypicFeature	D003967
20722491	1071	1077	nausea	DiseaseOrPhenotypicFeature	D009325
20722491	1079	1087	vomiting	DiseaseOrPhenotypicFeature	D014839
20722491	1089	1099	stomatitis	DiseaseOrPhenotypicFeature	D013280
20722491	1104	1122	hand-foot syndrome	DiseaseOrPhenotypicFeature	D060831
20722491	1124	1136	Capecitabine	ChemicalEntity	D000069287
20722491	1202	1210	patients	OrganismTaxon	9606
20722491	1230	1260	hepatic and renal dysfunctions	DiseaseOrPhenotypicFeature	D007674,D008107
20722491	Negative_Correlation	D005472	D013274	No
20722491	Negative_Correlation	D005472	D010190	No
20722491	Negative_Correlation	D005472	D002292	No
20722491	Negative_Correlation	D005472	D015179	No
20722491	Negative_Correlation	D005472	D006258	No
20722491	Negative_Correlation	D005472	D001943	No
20722491	Negative_Correlation	D005472	D009369	No
20722491	Association	D000069287	D008107	Novel
20722491	Association	D000069287	D007674	Novel
20722491	Positive_Correlation	D000069287	D060831	No
20722491	Positive_Correlation	D000069287	D013280	No
20722491	Positive_Correlation	D000069287	D014839	No
20722491	Positive_Correlation	D000069287	D009325	No
20722491	Positive_Correlation	D000069287	D003967	No
20722491	Negative_Correlation	D000069287	D013274	No
20722491	Negative_Correlation	D000069287	D010190	No
20722491	Negative_Correlation	D000069287	D002292	No
20722491	Negative_Correlation	D000069287	D015179	No
20722491	Negative_Correlation	D000069287	D006258	No
20722491	Negative_Correlation	D000069287	D001943	No